SHREE GANESH REMEDIES LTD
Latest filings
- Company Secretary resigns, replacement appointed from Oct 4 · Management Changes
- Company Secretary Aditya Patel resigns, Akanksha appointed as replacement · Management Changes
- Company Secretary resigns; new CS takes over from Oct 4 · Management Changes
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical intermediates and specialty chemicals, with a CRAMS (Contract Research and Manufacturing Services) arm covering agrochemicals, pharma, and electronics applications for clients in Europe and Japan. Operations are based in Ankleshwar, with a newly commissioned pilot plant and a Block 7 manufacturing expansion underway. FY26 revenue was ₹109.29 crore, essentially flat against ₹108.60 crore in FY25, though Q4 FY26 revenue grew 36% year-on-year to ₹33.20 crore on stronger pharma intermediates and specialty chemicals sales. Management framed FY26 as a 'year of consolidation', citing European market slowdown, geopolitical uncertainty, raw-material volatility, and customer deferrals as the main headwinds. EBITDA margin compressed to 32.0% in FY26 from 36.1% in FY25, finance costs nearly doubled to ₹356 lakh, and PAT fell 23% to ₹17.77 crore. Raw materials at 37.4% of revenue are the largest cost component.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
SGRL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from SHREE GANESH REMEDIES LTD's filed financials and exchange disclosures
What does SHREE GANESH REMEDIES LTD do?
SHREE GANESH REMEDIES LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SGRL.
Is SHREE GANESH REMEDIES LTD profitable?
Yes. Over the trailing twelve months SHREE GANESH REMEDIES LTD reported a net profit of ₹18 Cr on revenue of ₹109 Cr.
Does SHREE GANESH REMEDIES LTD pay a dividend?
Not in the latest reported year — SHREE GANESH REMEDIES LTD's dividend payout for FY26 was nil.
Is SHREE GANESH REMEDIES LTD debt-free?
No. It reported borrowings of ₹31 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹17 Cr after cash. Debt stands at 0.19× equity. That is higher than 54% of its 166 Pharmaceuticals peers.
Is SHREE GANESH REMEDIES LTD expensive compared with its peers?
On trailing P/E, SHREE GANESH REMEDIES LTD ranks 114 of 158 in Pharmaceuticals — cheaper than 28% of them, against an industry median of 31.2×. This is a position, not a valuation judgement.
Where can I track SHREE GANESH REMEDIES LTD's announcements?
Every NSE and BSE filing by SHREE GANESH REMEDIES LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.